|
| Time/Date | Code | Headline | Source | Impact |
|---|---|---|---|---|
| 07:00 19-Apr-2013 | RENE | Presentation on Mechanisms of Action | RNS | +1.73% |
| 16:40 17-Apr-2013 | RENE | Second Price Monitoring Extn | RNS | -5.29% |
| 16:35 17-Apr-2013 | RENE | Price Monitoring Extension | RNS | -5.29% |
| 16:40 04-Apr-2013 | RENE | Second Price Monitoring Extn | RNS | -2.87% |
| 16:35 04-Apr-2013 | RENE | Price Monitoring Extension | RNS | -2.87% |
| 07:02 28-Mar-2013 | RENE | Collaboration with Cell Therapy Catapult | RNS | -9.96% |
| 07:00 27-Mar-2013 | RENE | Dosing Completed in Stroke Trial | RNS | -7.03% |
| 07:00 26-Mar-2013 | RENE | Approvals for Stem Cell Trial in CLI | RNS | -4.32% |
| 16:40 19-Mar-2013 | RENE | Second Price Monitoring Extn | RNS | +4.76% |
| 16:35 19-Mar-2013 | RENE | Price Monitoring Extension | RNS | +4.76% |
| 07:00 11-Mar-2013 | RENE | Wins Two Biomedical Catalyst Grants | RNS | +0.81% |
| 16:35 06-Mar-2013 | RENE | Price Monitoring Extension | RNS | -4.80% |
| 07:00 25-Feb-2013 | RENE | AIM Rule 17 Notification | RNS | +15.83% |
| 07:00 29-Jan-2013 | RENE | Stroke Trial Update: Final Cohort Begins Dosing | RNS | -13.62% |
| 16:40 11-Jan-2013 | RENE | Second Price Monitoring Extn | RNS | +21.68% |
| 16:35 11-Jan-2013 | RENE | Price Monitoring Extension | RNS | +21.68% |
| 07:01 04-Dec-2012 | RENE | ReNeuron to Present at UK Stroke Forum | RNS | -3.84% |
| 07:00 04-Dec-2012 | RENE | Interim Results | RNS | -3.84% |
| 07:00 22-Nov-2012 | RENE | Non-Clinical Data | RNS | +0.92% |
| 07:00 21-Nov-2012 | RENE | Notification of Interim Results | RNS | +5.20% |
The Exchange accepts no responsibility for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.
By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.
You will be redirected in five seconds.
You are accessing the London Stock Exchange Annual Report Service powered by PrecisionIR.
The Exchange accepts no responsibility for the content of the reports you are now accessing or for any reliance placed by you or any person on the information contained therein.
By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.
You will be redirected in five seconds